N/A N=4,561 Influenza Resistance Information Study
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
N/A N=178 Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
Phase 3 N=7,250 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Influenza
Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…
Phase 1 N=95 Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally
Influenza
Primary: Antibody Responses in Nasal Secretions to Influenza A/H1N1 and A/H3N2 at 14 Days After Intranasal Immunization. — 3; 3; 5; 0 Participants
N/A N=46 Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
Influenza
Primary: Area Under the Curve of Virus Load — -2081.98; 18,973.90; 15,944.09; 12,201.14 mins*Eq log10 TCID50/mL
N/A N=558 Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza
Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Phase 1 N=45 Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs
Phase 2 N=150 Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
Influenza
Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants
N/A N=33 Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
Influenza A H3N2
Primary: Occurrence of Adverse Events Related to the Viral Challenge — 0; 0; 1; 6 Occurrence of adverse events
Phase 1 N=76 H1N1v Virus Challenge Study in Healthy Subjects
Influenza
Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…
Phase 1 N=35 Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus
Influenza
Primary: Viral Shedding — 8; 4; 7; 4 Participants
Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
Influenza
Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants
Phase 1 N=63 First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
Influenza · Seasonal Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 4; 12; 9; 8 Participants
Phase 4 N=13 The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 3; 8 Participants
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
Phase 3 N=329 Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Influenza A · Influenza B
Primary: Number of Patients in Each of 6 Clinical Status Categories on Day 7 — 3; 2; 6; 11 Participants — p=.33
N/A N=1,839 Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015
Influenza, Human
Primary: Number of Seasonal Influenza A and /or B Cases by Age Group, in Panama (Using the Data Reported Via National Influenza Surveillance Program) — 448; 120; 123; 47…
Phase 1 N=27 Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Influenza Type A · Influenza Type B · Influenza
Primary: Number of Participants Having Adverse Events — 0; 1; 1; 1 Participants
Phase 3 N=3,670 Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)
Influenza
Primary: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens — 35; 62 Participants
Phase 3 N=12,794 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases
Primary: Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI) Due to Any Laboratory-Confirmed Influenza Strains — 118; 130 Number of cases
Phase 3 N=889 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3
Influenza, Human
Primary: Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE) — 1; 0; 1; 0 Participants
Phase 4 N=984 Inactivated Influenza Via Jet Injection
Influenza, Human
Primary: Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) — 3.80; 3.77; 5.72; 5.70 Titers
N/A N=1,849 Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada
Influenza
Primary: Age Adjusted Percentage of Participants With a Physician Visit Due to Any Diagnosis Within 30 Days of the Index Date of the Confirmed Influenza A and B Cases in the…
Phase 1 N=25 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults
Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants
Phase 3 N=1,801 Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
Influenza
Primary: Hemagglutination Inhibition Antibody (HIA) Titer for Each of the Three Antigens Contained in the Vaccine — 269.7; 337.3; 288.5; 297.1 Titers